Synthesis of [13C2,15n]‐1,3‐2h‐1‐benzyl‐(z)‐3‐(benzylidene)indolin‐2‐one

Jixia Yang,Gongzheng Zhang,Zhaoyang Wang,Zhanxiong Xiao,Hongliang Wen
DOI: https://doi.org/10.1002/jlcr.3796
2019-01-01
Journal of Labelled Compounds and Radiopharmaceuticals
Abstract:Parkinson disease (PD) is a neurodegenerative disorder characterized by the accumulation of α‐synuclein into Lewy bodies. 3‐Benzylidine‐indolin‐2‐one represents a class of compounds, which are known to inhibit the accumulation of α‐synuclein. In this paper, we report the synthesis of [13C] and [15N] labelled 1‐benzyl‐(Z)‐3‐(benzylidene)indolin‐2‐one from commercially available [13C2]‐chloroacetic acid and [15N]‐aniline in five steps. The product will be used to study its metabolites in human liver microsomes by liquid chromatography‐tandem mass spectrometry.
What problem does this paper attempt to address?